Indeed, we showed that the ONCE protocol might be an informative approach to monitor ERBB2 in breast cancer patients without genomic ERBB2 amplification or patients that are HER2 positive at diagnosis and turn negative after multiple cycles of therapy (Bon et al., 2020; Branco et al., 2019). The gene discussed is ERBB2; the disease is breast cancer.